Transaction formally closed in the first quarter of 2016 / Laboratory and office space will be near Kendall Square in Cambridge, MA / Hiring is underway and efforts have begun on initial programs in hematology and ophthalmology Leverkusen, Germany and Basel, Switzerland, August 19, 2016 – Casebia Therapeutics, the joint venture founded by Bayer and […]
The novel joint venture focuses on fundamental breakthrough treatments through first systemic application of promising CRISPR-Cas9 gene editing technology / Bayer is investing USD 335 million in a long-term alliance with CRISPR Therapeutics through new Bayer LifeScience Center unit / The joint venture will combine two leading knowledge areas: CRISPR-Cas9 from CRISPR Therapeutics as well […]
Dr. Abigail Doyle (Associate Professor at Princeton University, USA) wins the „Chemistry“ category / Dr. Steven Spoel (Principal Investigator at the University of Edinburgh, UK) takes the „Biology“ award /Dr. Javier Fernandez (Associate Researcher at Wyss Institute/Harvard University, Boston, USA) awarded prize in the „Materials“ field Leverkusen, January 10, 2013 – The winners of the Bayer […]
Special global web conference “One Health” to address zoonotic disease within the veterinary and public health fields Leverkusen, January 9, 2014 – Nearly half of the world’s population is infected with at least one type of vector-borne disease (1). These diseases are transmitted from parasites to animals and humans, and have a significant impact on public health […]
TARRYTOWN, N.Y., Dec. 18, 2013 /PRNewswire/ — Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for standard review the Company’s supplemental Biologics License Application (sBLA) for EYLEA® (aflibercept) Injection for the treatment of Diabetic Macular Edema (DME). Under the Prescription Drug User Fee Act (PDUFA), the goal for a standard review of an sBLA […]